230 related articles for article (PubMed ID: 22087029)
1. Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
Hempe J; Elvert R; Schmidts HL; Kramer W; Herling AW
Lab Anim; 2012 Jan; 46(1):32-9. PubMed ID: 22087029
[TBL] [Abstract][Full Text] [Related]
2. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS
Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
[TBL] [Abstract][Full Text] [Related]
3. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats.
Oltman CL; Coppey LJ; Gellett JS; Davidson EP; Lund DD; Yorek MA
Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E113-22. PubMed ID: 15727946
[TBL] [Abstract][Full Text] [Related]
4. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.
Pelzer T; Jazbutyte V; Arias-Loza PA; Segerer S; Lichtenwald M; Law MP; Schäfers M; Ertl G; Neyses L
Biochem Biophys Res Commun; 2005 Apr; 329(2):726-32. PubMed ID: 15737646
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
Baylis C; Atzpodien EA; Freshour G; Engels K
J Pharmacol Exp Ther; 2003 Dec; 307(3):854-60. PubMed ID: 14560039
[TBL] [Abstract][Full Text] [Related]
7. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment.
Pickavance L; Widdowson PS; King P; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Oct; 125(4):767-70. PubMed ID: 9831913
[TBL] [Abstract][Full Text] [Related]
8. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin.
Katsuda Y; Sasase T; Tadaki H; Mera Y; Motohashi Y; Kemmochi Y; Toyoda K; Kakimoto K; Kume S; Ohta T
Exp Anim; 2015; 64(2):161-9. PubMed ID: 25736710
[TBL] [Abstract][Full Text] [Related]
9. Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart.
Wang P; Chatham JC
Am J Physiol Endocrinol Metab; 2004 May; 286(5):E725-36. PubMed ID: 14722022
[TBL] [Abstract][Full Text] [Related]
10. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
Nakano R; Kurosaki E; Shimaya A; Kajikawa S; Shibasaki M
Eur J Pharmacol; 2006 Nov; 549(1-3):185-91. PubMed ID: 16989806
[TBL] [Abstract][Full Text] [Related]
11. Diabetes in Zucker diabetic fatty rat.
Shiota M; Printz RL
Methods Mol Biol; 2012; 933():103-23. PubMed ID: 22893404
[TBL] [Abstract][Full Text] [Related]
12. Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure.
Goh TT; Mason TM; Gupta N; So A; Lam TK; Lam L; Lewis GF; Mari A; Giacca A
Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E549-60. PubMed ID: 17003242
[TBL] [Abstract][Full Text] [Related]
13. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
14. Capillary endothelial but not lymphatic function is restored under rosiglitazone in Zucker diabetic fatty rats.
Cosson E; Cohen-Boulakia F; Tarhzaoui K; Dabiré H; Léger G; Charnaux N; Lestrade R; Behar A; Valensi P
Microvasc Res; 2009 Mar; 77(2):220-5. PubMed ID: 19109983
[TBL] [Abstract][Full Text] [Related]
15. Increased aldosterone levels in a model of type 2 diabetes mellitus.
Fredersdorf S; Endemann DH; Luchner A; Heitzmann D; Ulucan C; Birner C; Schmid P; Stoelcker B; Resch M; Muders F; Riegger GA; Weil J
Exp Clin Endocrinol Diabetes; 2009 Jan; 117(1):15-20. PubMed ID: 18726873
[TBL] [Abstract][Full Text] [Related]
16. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
[TBL] [Abstract][Full Text] [Related]
17. Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.
Schäfer S; Schmidts HL; Bleich M; Busch AE; Linz W
Br J Pharmacol; 2004 Sep; 143(1):27-32. PubMed ID: 15289289
[TBL] [Abstract][Full Text] [Related]
18. Aerobic training and diabetic nephropathy in the obese Zucker rat.
Ward KM; Mahan JD; Sherman WM
Ann Clin Lab Sci; 1994; 24(3):266-77. PubMed ID: 8048799
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.
Wessels B; Ciapaite J; van den Broek NM; Houten SM; Nicolay K; Prompers JJ
Diabetes Obes Metab; 2015 Jan; 17(1):52-60. PubMed ID: 25200673
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Toblli JE; Cao G; Giani JF; Muñoz MC; Angerosa M; Dominici FP
J Hypertens; 2011 Aug; 29(8):1613-23. PubMed ID: 21720265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
